Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Arvinas Holding Company (ARVN)
NASDAQ:ARVN
RESEARCH TOOLSreports
Holding ARVN?
Track your performance easily
Earnings Data
Report Date
Mar 03, 2025TBA Not Confirmed
Period Ending
2024 (Q4)Consensus EPS Forecast
-$0.96Last Year’s EPS
-$2.53Same Quarter Last Year
Strong Buy
Based on 16 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Oct 30, 2024
|% Change Since: -32.80%
|Next Earnings Date:Mar 03, 2025
Earnings Call Sentiment|Positive
The earnings call was largely positive, highlighting significant revenue growth, a strong financial position, and promising advancements in their pipeline, particularly the vepdegestrant program. However, there are concerns about increased expenses and dependency on future clinical trial data.Company Guidance
During the earnings call for Arvinas' third quarter of 2024, the company provided guidance on several key metrics and developments. They announced a revenue of $102.4 million for the quarter, a significant increase from $34.6 million in the same period of 2023, primarily driven by a $76.7 million revenue from the Novartis license agreement. The company reported having $1.1 billion in cash, cash equivalents, and marketable securities, which they believe will support operations into 2027. Their financial strategy is focused on advancing the vepdegestrant (vepdeg) clinical program, with Phase 3 trials anticipated to start in 2025, and preparing for potential commercialization. Arvinas is on track to share top-line data from the pivotal VERITAC-2 Phase 3 trial by the end of 2024 or the first quarter of 2025, which will be a landmark event for the company. This trial evaluates vepdeg as a monotherapy and in combination with other agents in ER-positive/HER2-negative breast cancer, with the goal of demonstrating superior efficacy and tolerability compared to fulvestrant. Additionally, the company is advancing its PROTAC discovery platform across oncology and neuroscience, with initial data from ARV-102 expected in 2025.Strong Financial Position
Arvinas reported having $1.1 billion in cash, cash equivalents, and marketable securities, sufficient to support operations into 2027.
Significant Revenue Increase
The company recorded $102.4 million in revenue for the quarter, a significant increase from $34.6 million in the same period in 2023, primarily due to the Novartis license agreement.
Advancements in Vepdegestrant Program
Progress in the VERITAC-2 trial with a top line data readout expected by the end of 2024 or first quarter of 2025. The trial is a landmark event for Arvinas and could lead to the first-ever regulatory approval of a PROTAC degrader.
Pipeline Expansion
Arvinas is advancing a broad pipeline across oncology and neuroscience, including programs like ARV-102 for neurodegenerative disorders and ARV-393 for B-cell lymphomas.
---
ARVN Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
ARVN Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Oct 30, 2024 | $27.50 | $27.66 | +0.58% |
| Jul 30, 2024 | $27.78 | $27.09 | -2.48% |
| May 07, 2024 | $32.26 | $34.33 | +6.42% |
| Feb 27, 2024 | $48.79 | $48.01 | -1.60% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Arvinas Holding Company (ARVN) report earnings?
Arvinas Holding Company (ARVN) is schdueled to report earning on Mar 03, 2025, TBA Not Confirmed.
What is Arvinas Holding Company (ARVN) earnings time?
Arvinas Holding Company (ARVN) earnings time is at Mar 03, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is ARVN EPS forecast?
ARVN EPS forecast for the fiscal quarter 2024 (Q4) is -$0.96.
---